AbbVie Announces $1.4 Billion Investment in Durham Manufacturing Campus
On April 22, 2026, Governor Josh Stein announced that AbbVie Inc. (NYSE: ABBV) will invest $1.4 billion to construct a new pharmaceutical manufacturing campus in Durham, North Carolina. This marks AbbVie’s first major investment in the state and represents the company’s largest single-campus capital investment to date.
The 185-acre facility will support the production of AbbVie’s immunology, neuroscience and oncology medicines, integrating advanced manufacturing technologies with artificial intelligence. Construction is set to begin in 2026, with completion expected by the end of 2028.
The project will create 734 full-time jobs upon completion and generate more than 2,000 construction jobs during the development phase. AbbVie states that this investment is part of its broader $100 billion commitment to U.S. Research and development (R&D) and capital investments, including manufacturing, over the next decade.
Economic Impact on North Carolina
Governor Stein emphasized that the investment strengthens North Carolina’s position as a leader in the life sciences industry. “When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business,” he said.
The Durham campus will serve as a U.S. Center of excellence for sterile fill-finish (SVP) manufacturing, further enhancing the state’s capabilities in advanced pharmaceutical production.
About AbbVie’s Investment Strategy
AbbVie’s Chairman and CEO, Robert A. Michael, described the Durham facility as a significant milestone for the company. “By establishing this campus, we are strengthening our ability to support future medical breakthroughs even as likewise creating new jobs and a long-term partnership with Durham and the State of North Carolina,” Michael stated.
The investment aligns with AbbVie’s strategy to expand its U.S. Manufacturing footprint and support long-term growth in key therapeutic areas. The company currently employs approximately 29,000 people across the United States and Puerto Rico.
Project Timeline and Details
- Investment Amount: $1.4 billion
- Campus Size: 185 acres
- Location: Durham, North Carolina
- Jobs Created: 734 full-time positions
- Construction Jobs: More than 2,000
- Construction Start: 2026
- Expected Completion: End of 2028
- Supported Therapies: Immunology, neuroscience, and oncology
- Technology Integration: Advanced manufacturing and artificial intelligence
Frequently Asked Questions
Is this AbbVie’s first investment in North Carolina?
Yes, this represents AbbVie’s first major investment in the state of North Carolina.
How does this investment fit into AbbVie’s broader plans?
The $1.4 billion Durham campus is part of AbbVie’s $100 billion commitment to U.S. Research and development and capital investments, including manufacturing, over the next decade.
What types of jobs will be created?
The project will create 734 full-time manufacturing and operations positions, along with more than 2,000 temporary construction jobs during the build-out phase.
When will the facility be operational?
Construction begins in 2026, with completion expected by the end of 2028.
Key Takeaways
- AbbVie is investing $1.4 billion in a new manufacturing campus in Durham, North Carolina.
- The project marks the company’s largest single-campus investment to date.
- It will create 734 permanent jobs and over 2,000 construction positions.
- The facility will produce immunology, neuroscience, and oncology medicines using advanced AI-integrated manufacturing.
- This investment supports AbbVie’s $100 billion U.S. R&D and manufacturing commitment over ten years.
- Construction starts in 2026, with completion targeted for the end of 2028.
AbbVie’s investment in Durham underscores the growing importance of North Carolina’s life sciences ecosystem and highlights the state’s ability to attract major biopharmaceutical investments. As construction progresses over the next few years, the project is expected to deliver significant economic benefits to the region while advancing AbbVie’s manufacturing capabilities for critical medicines.